October 3, 2023
Novartis reports positive data from the Phase III APPLAUSE study which reinforces the potential of iptacopan
Novartis announced Monday positive top-line results from the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study (NCT04578834) at 9 months.